Joshua J Meeks (Joshua Meeks)

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 37

Top Topics

Epidermal Growth Factor Receptor

Muscle Invasive Bladder Cancer

Top Venues

Nature medicine

Proceedings of the National Academy of Sciences of the United States of America

Journal for immunotherapy of cancer

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Ioana Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Guenter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Joerg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua J Meeks, Francisco Emilio Vera-Badillo, José Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Gruenwald, Michael Hudecek, Markus Eckstein
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine (2024)
Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J Meeks
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer. Journal for immunotherapy of cancer 12 (4) (2024)
Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J Meeks
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer. Journal for immunotherapy of cancer 12 (4) (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine (2024)
Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J Meeks
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer. Journal for immunotherapy of cancer 12 (4) (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine 30 (8) (2024)
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Ioana Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Guenter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Joerg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua J Meeks, Francisco Emilio Vera-Badillo, José Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Gruenwald, Michael Hudecek, Markus Eckstein
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (20) (2024)
Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J Meeks
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer. Journal for immunotherapy of cancer 12 (4) (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine (2024)
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Ioana Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Guenter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Joerg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua J Meeks, Francisco Emilio Vera-Badillo, José Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Gruenwald, Michael Hudecek, Markus Eckstein
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (20) (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine (2024)
Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J Meeks
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer. Journal for immunotherapy of cancer 12 (4) (2024)
Khyati Meghani, Noah Frydenlund, Yanni Yu, Bonnie Choy, Joshua J Meeks
Spatial comparison of molecular features associated with resistance to pembrolizumab in BCG unresponsive bladder cancer. Journal for immunotherapy of cancer 12 (4) (2024)
Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Ioana Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Guenter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack, Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Theresa Mokry, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Dimo Dietrich, Jonas Saal, Joerg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua J Meeks, Francisco Emilio Vera-Badillo, José Alberto Nakauma-González, Joost Boormans, Kerstin Junker, Arndt Hartmann, Viktor Gruenwald, Michael Hudecek, Markus Eckstein
NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (20) (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Author Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Publisher Correction: Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine (2024)
Roger Li, Paras H Shah, Tyler F Stewart, Jong Kil Nam, Trinity J Bivalacqua, Donald L Lamm, Edward M Uchio, Daniel M Geynisman, Joseph M Jacob, Joshua J Meeks, Rian Dickstein, Shane M Pearce, Seok Ho Kang, Seung Il Jung, Ashish M Kamat, James M Burke, Kirk A Keegan, Gary D Steinberg
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nature medicine 30 (8) (2024)
Zibo Zhao, Yuki Aoi, Cassandra N Philips, Khyati A Meghani, Sarah R Gold, Yanni Yu, Luke St John, Jun Qian, Jacob M Zeidner, Joshua J Meeks, Ali Shilatifard
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences of the United States of America 120 (52) (2023)
Zibo Zhao, Yuki Aoi, Cassandra N Philips, Khyati A Meghani, Sarah R Gold, Yanni Yu, Luke St John, Jun Qian, Jacob M Zeidner, Joshua J Meeks, Ali Shilatifard
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences of the United States of America 120 (52) (2023)
A Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro Antonio Alves Castro, Clarice S Groeneveld, Aurélien de Reyniès, Vadim I Nazarov, Vasily O Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J Meeks
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature communications 14 (1) (2023)
A Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro Antonio Alves Castro, Clarice S Groeneveld, Aurélien de Reyniès, Vadim I Nazarov, Vasily O Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J Meeks
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature communications 14 (1) (2023)
A Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro Antonio Alves Castro, Clarice S Groeneveld, Aurélien de Reyniès, Vadim I Nazarov, Vasily O Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J Meeks
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature communications 14 (1) (2023)
Zibo Zhao, Yuki Aoi, Cassandra N Philips, Khyati A Meghani, Sarah R Gold, Yanni Yu, Luke St John, Jun Qian, Jacob M Zeidner, Joshua J Meeks, Ali Shilatifard
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences of the United States of America 120 (52) (2023)
Zibo Zhao, Yuki Aoi, Cassandra N Philips, Khyati A Meghani, Sarah R Gold, Yanni Yu, Luke St John, Jun Qian, Jacob M Zeidner, Joshua J Meeks, Ali Shilatifard
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences of the United States of America 120 (52) (2023)
A Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro Antonio Alves Castro, Clarice S Groeneveld, Aurélien de Reyniès, Vadim I Nazarov, Vasily O Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J Meeks
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature communications 14 (1) (2023)
Zibo Zhao, Yuki Aoi, Cassandra N Philips, Khyati A Meghani, Sarah R Gold, Yanni Yu, Luke St John, Jun Qian, Jacob M Zeidner, Joshua J Meeks, Ali Shilatifard
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences of the United States of America 120 (52) (2023)
Zibo Zhao, Yuki Aoi, Cassandra N Philips, Khyati A Meghani, Sarah R Gold, Yanni Yu, Luke St John, Jun Qian, Jacob M Zeidner, Joshua J Meeks, Ali Shilatifard
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences of the United States of America 120 (52) (2023)
A Gordon Robertson, Khyati Meghani, Lauren Folgosa Cooley, Kimberly A McLaughlin, Leigh Ann Fall, Yanni Yu, Mauro Antonio Alves Castro, Clarice S Groeneveld, Aurélien de Reyniès, Vadim I Nazarov, Vasily O Tsvetkov, Bonnie Choy, Daniele Raggi, Laura Marandino, Francesco Montorsi, Thomas Powles, Andrea Necchi, Joshua J Meeks
Expression-based subtypes define pathologic response to neoadjuvant immune-checkpoint inhibitors in muscle-invasive bladder cancer. Nature communications 14 (1) (2023)
Zibo Zhao, Yuki Aoi, Cassandra N Philips, Khyati A Meghani, Sarah R Gold, Yanni Yu, Luke St John, Jun Qian, Jacob M Zeidner, Joshua J Meeks, Ali Shilatifard
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences of the United States of America 120 (52) (2023)
Seth P Lerner, David J McConkey, Catherine M Tangen, Joshua J Meeks, Thomas W Flaig, Xing Hua, Siamak Daneshmand, Ajjai Shivaram Alva, M Scott Lucia, Dan Theodorescu, Amir Goldkorn, Matthew I Milowsky, Woonyoung Choi, Rick Bangs, Daniel L Gustafson, Melissa Plets, Ian M Thompson
Association of Molecular Subtypes with Pathologic Response, PFS and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Zibo Zhao, Yuki Aoi, Cassandra N Philips, Khyati A Meghani, Sarah R Gold, Yanni Yu, Luke St John, Jun Qian, Jacob M Zeidner, Joshua J Meeks, Ali Shilatifard
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences of the United States of America 120 (52) (2023)
Zibo Zhao, Yuki Aoi, Cassandra N Philips, Khyati A Meghani, Sarah R Gold, Yanni Yu, Luke St John, Jun Qian, Jacob M Zeidner, Joshua J Meeks, Ali Shilatifard
Somatic mutations of MLL4/COMPASS induce cytoplasmic localization providing molecular insight into cancer prognosis and treatment. Proceedings of the National Academy of Sciences of the United States of America 120 (52) (2023)
Andrea Piunti, Khyati Meghani, Yanni Yu, A Gordon Robertson, Joseph R Podojil, Kimberly A McLaughlin, Zonghao You, Damiano Fantini, MingYi Chiang, Yi Luo, Lu Wang, Nathan Heyen, Jun Qian, Stephen D Miller, Ali Shilatifard, Joshua J Meeks
Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. Science advances 8 (40) (2022)